Skip to main content
Log in

Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically based pharmacokinetic (PBPK) modeling: analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population

  • Toxicokinetics and Metabolism
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Abstract

As a toxic substance, 4-n-nonylphenol (4-n-NP) or 4-nonylphenol (4-NP) is widely present in the environment. 4-n-NP is a single substance with a linear-alkyl side chain, but 4-NP usually refers to a random mixture containing various branched types. Unfortunately, human risk assessment and/or exposure level analysis for 4-n-NP (or 4-NP) were almost nonexistent, and related research was urgently needed. This study aimed to analyze the various exposures of 4-n-NP (or 4-NP) through development of a physiologically based-pharmacokinetic (PBPK) model considering gender difference in pharmacokinetics of 4-n-NP and its application to human risk assessment studies. A PBPK model was newly developed considering gender differences in 4-n-NP pharmacokinetics and applied to a human risk assessment for each gender. Exposure analysis was performed using a PBPK model that considered gender differences in 4-n-NP (or 4-NP) exposure and high variabilities in several countries. Furthermore, an extended application was attempted as a human risk assessment for random mixture 4-NP, which is difficult to accurately evaluate in reality. External-exposure and margin-of-safety estimated with the same internal exposure amount differed between genders, meaning the need for a differentiated risk assessment considering gender. Exposure analysis based on biomonitoring data confirmed large variability in exposure to 4-n-NP (or 4-NP) by country, group, and period. External-exposures estimated using PBPK model varied widely, ranging from 0.039 to 63.875 mg/kg/day (for 4-n-NP or 4-NP). By country, 4-n-NP (or 4-NP) exposure was higher in females than in males and the margin-of-safety tended to be low. Overall, exposure to 4-n-NP (or 4-NP) in populations was largely not safe, suggesting need for ongoing management and monitoring. Considering low in vivo accumulation confirmed by PBPK model, risk reduction of 4-n-NP is possible by reducing its use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Abbreviations

4-n-NP:

4-n-Nonylphenol

4-NP:

4-Nonylphenol

PBPK:

Physiologically based pharmacokinetic

UHPLC-ESI-MS/MS:

Ultrahigh performance liquid chromatography electrospray ionization mass spectrometry

GI:

Gastrointestinal

ESI:

Electrospray ionization

RMSE:

Root mean squared error

AIC:

Akaike’s information criterion

CI:

Confidence interval

ANOVA:

Analysis of variance

NOAEL:

No observed adverse effect level

POD:

Point of departure

CV:

Coefficient of variation

References

Download references

Acknowledgements

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health and Welfare, Republic of Korea (No. HI21C1032). This research was also supported by a grant of the Basic Science Research Program through the National Research Foundation (NRF) funded by the Ministry of Education, Republic of Korea (No. 2021R1A6A3A03039851).

Author information

Authors and Affiliations

Authors

Contributions

S-HJ conceptualization, investigation, methodology, writing—original draft, writing—review and editing, software, data analysis, visualization; J-HJ conceptualization, investigation, writing—review and editing, software, data analysis; H-YC writing—review, project administration, conceptualization; YB L conceptualization, methodology, writing—review and editing, funding acquisition, supervision.

Corresponding author

Correspondence to Yong-Bok Lee.

Ethics declarations

Conflict of interest

The authors declare that there are no conflicts of interests regarding the publication of this paper.

Ethical approval

All animal experiments were approved by Chonnam National University Animal Experimental Ethics Committee (No. CNU IACUC-YB-2020-60 and CNU IACUC-YB-2017-45), Republic of Korea. This study was performed according to revised Guidelines for Ethical Conduct in the Care and Use of Animals and rules of Good Laboratory Practice.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 22 KB)

Supplementary file2 (DOCX 768 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jeong, SH., Jang, JH., Cho, HY. et al. Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically based pharmacokinetic (PBPK) modeling: analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population. Arch Toxicol 96, 2687–2715 (2022). https://doi.org/10.1007/s00204-022-03328-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00204-022-03328-9

Keywords

Navigation